Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–
2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)
Bipolar Androgen Therapy- hear Dr. Sam Denmeade, Johns Hopkins 2/20/17 – 8pm EST
Bipolar Androgen Therapy (BAT) is one of the hottest topics in prostate cancer right now for men with metastatic disease. Counter intuitive as it is, trials have shown large doses of testosterone followed by hormone therapy or chemotherapy appear to be very effective for some men in reducing PSA – for an excellent commentary by Mike Scott on Prostate Cancer International, click here.
Dr. Sam Denmeade at Johns Hopkins Medicine is in the forefront of this research. On Monday, February 20 at 8pm EST, Dr. Denmeade explained his research and open clinical trials on Answer Cancer Foundation’s UsTOO Hi-risk/Recurrent/Advanced Prostate Cancer Virtual Support Group meeting.
To review Dr. Denmeade’s slide presentation, click here
Listen to and watch the the whole presentation here.
If interested in contacting Dr. Denmeade for more information on BAT trials or your suitability, please e-mail him at denmesa@jhmi.edu .
Click the PDF icon for the deck
And an update ….. here’s a link to a UroToday interview between Chuck Ryan and Sam Denmead and Michael Schweitzer in Autumn, 2019.
